{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T01:50:59Z","timestamp":1745545859512},"reference-count":18,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2023.14199","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T12:01:53Z","timestamp":1703073713000},"source":"Crossref","is-referenced-by-count":2,"title":["Hypopituitarism induced by pembrolizumab plus axitinib in the treatment of metastatic renal cell carcinoma: A case report"],"prefix":"10.3892","volume":"27","author":[{"given":"Kazushi","family":"Hanawa","sequence":"first","affiliation":[{"name":"Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409\u20113821, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norifumi","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409\u20113821, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junki","family":"Aikawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409\u20113821, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Otake","sequence":"additional","affiliation":[{"name":"Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409\u20113821, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Kasai","sequence":"additional","affiliation":[{"name":"Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409\u20113821, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keito","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409\u20113821, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Shimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409\u20113821, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409\u20113821, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoru","family":"Kira","sequence":"additional","affiliation":[{"name":"Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409\u20113821, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiko","family":"Mitsui","sequence":"additional","affiliation":[{"name":"Department of Urology, Interdisciplinary Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi 409\u20113821, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"key":"key20240125115023_b1-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"key20240125115023_b2-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"key":"key20240125115023_b3-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"key20240125115023_b4-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","article-title":"Lessons learned from the blockade of immune checkpoints in cancer immunotherapy","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"key20240125115023_b5-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.3390\/ijms17071151","article-title":"A mini-review for cancer immunotherapy: Molecular understanding of PD-1\/PD-L1 pathway & translational blockade of immune checkpoints","volume":"17","author":"Li","year":"2016","journal-title":"Int J Mol Sci"},{"key":"key20240125115023_b6-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"key20240125115023_b7-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan endocrine society","volume":"66","author":"Arima","year":"2019","journal-title":"Endocr J"},{"key":"key20240125115023_b8-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12916-015-0455-8","article-title":"Immune related adverse events associated with anti-CTLA-4 antibodies: Systematic review and meta-analysis","volume":"13","author":"Bertrand","year":"2015","journal-title":"BMC Med"},{"key":"key20240125115023_b9-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20240125115023_b10-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): Extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20240125115023_b11-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"key20240125115023_b12-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: Insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli","year":"2016","journal-title":"Am J Pathol"},{"key":"key20240125115023_b13-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1007\/s00262-021-02955-y","article-title":"Mechanistic insights into immune checkpoint inhibitor-related hypophysitis: A form of paraneoplastic syndrome","volume":"70","author":"Kanie","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"key20240125115023_b14-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"527","DOI":"10.2169\/internalmedicine.9074-17","article-title":"Isolated adrenocorticotropin deficiency due to nivolumab-induced hypophysitis in a patient with advanced lung adenocarcinoma: A case report and literature review","volume":"57","author":"Ohara","year":"2018","journal-title":"Intern Med"},{"key":"key20240125115023_b15-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"key20240125115023_b16-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20240125115023_b17-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1093\/jjco\/hyab141","article-title":"Hypopituitarism in patients with metastatic renal cell carcinoma treated with ipilimumab and nivolumab combination therapy","volume":"51","author":"Takagi","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"key20240125115023_b18-ol-27-2-14199","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: Extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2024,1,25]],"date-time":"2024-01-25T09:51:38Z","timestamp":1706176298000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2023.14199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,12,20]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2023.14199","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"article-number":"66"}}